Systemic Lupus Erythematous SLE Drugs Market Segments and Forecast By End-use Industry 2015-2025
Future Market Insights has announced the addition of the “Systemic Lupus Erythematous SLE Drugs Market: Global Industry Analysis and Opportunity Assessment 2015-2025” report to their offering.
Future Market Insights has announced the addition of the “Systemic Lupus Erythematous SLE Drugs Market: Global Industry Analysis and Opportunity Assessment 2015-2025” report to their offering.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Global <strong>Systemic</strong><br />
<strong>Lupus</strong> <strong>Erythematous</strong><br />
<strong>SLE</strong> <strong>Drugs</strong> <strong>Market</strong><br />
Share, Global Trends,<br />
Analysis, Research, Report,<br />
Opportunities,<br />
Segmentation <strong>and</strong> <strong>Forecast</strong>,<br />
<strong>2015</strong>-<strong>2025</strong><br />
Future <strong>Market</strong> Insights<br />
www.futuremarketinsights.com<br />
sales@futuremarketinsights.com
Future <strong>Market</strong> Insights (FMI) is a premier provider of syndicated research reports, custom research reports, <strong>and</strong> consulting<br />
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,<br />
technology inputs, valuable growth insights, aerial view of the competitive framework, <strong>and</strong> future market trends.<br />
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, <strong>and</strong> BRIC.<br />
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, <strong>and</strong><br />
Retail.<br />
We have a global presence with delivery centers across India specializing in providing global research reports <strong>and</strong> country<br />
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.<br />
We combine our knowledge <strong>and</strong> learning from every corner of the world to distill it to one thing – the perfect solution for<br />
our client.<br />
Research Capabilities<br />
• Customized Research<br />
• Syndicated Research<br />
• Investment Research<br />
• Social Media Research<br />
Sector Coverage<br />
• Automotive <strong>and</strong> Transportation<br />
• Electronics, Semiconductor, <strong>and</strong> ICT<br />
• Retail <strong>and</strong> Consumer Products<br />
• Industrial Automation <strong>and</strong> Equipment<br />
• Chemicals & Materials<br />
• Food <strong>and</strong> Beverages<br />
• Services <strong>and</strong> Utilities<br />
• Energy, Mining, Oil, <strong>and</strong> Gas<br />
Customized<br />
Research<br />
Syndicated<br />
Research<br />
Investment<br />
Research<br />
Social Media<br />
Research<br />
Subscription Information<br />
For detailed subscription information please contact<br />
Hari. T (Sr. Manager - Global Business Development)<br />
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268<br />
Email: hari.t@futuremarketinsights.com
Report Description<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) is a chronic autoimmune disease which ca<strong>use</strong>s the immune<br />
system to mistakenly attack health body tissue. In <strong>SLE</strong>, body immune system can affect any part<br />
of the body, such as joints, organs, eyes, skin, etc. Often <strong>SLE</strong> can result in symptoms such as<br />
malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis,<br />
serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever,<br />
Raynaud’s phenomenon, livedo reticularis, thrombosis, <strong>and</strong> myositis. It is also known as a<br />
disease of flare-ups <strong>and</strong> remissions <strong>and</strong> can range from mild to life threatening severity. It is also<br />
called as drug-induced lupus erythematosus due to common observation against drugs such as<br />
isoniazid, hydralazine <strong>and</strong> procainamide. Currently, there is no complete treatment for <strong>SLE</strong>.<br />
While only two biologic agents have been approved by FDA to treat <strong>SLE</strong>, synthetic drugs are still<br />
the mainstay of therapy in <strong>SLE</strong>. Based on available evidence, azathioprine <strong>and</strong> mycophenolate<br />
mofetil are the drugs of first choice. Hydroxychloroquine should be considered an anchor drug<br />
in <strong>SLE</strong> beca<strong>use</strong> of the multiple beneficial effects of this agent.<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> <strong>Market</strong>: Drivers & Restraints<br />
Global <strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> market is projected to grow due to high<br />
prevalence of autoimmune diseases particularly systemic lupus erythematous (<strong>SLE</strong>). Major<br />
drivers for global systemic erythematous drugs market are development of novel <strong>SLE</strong> therapies,<br />
increasing availability of bio similar drugs <strong>and</strong> increasing support for emerging research areas for<br />
new drug molecules. At the same time, increasing awareness of disease diagnosis <strong>and</strong> treatment<br />
as well as consistent research <strong>and</strong> development processes for novel drug molecules are<br />
important drivers for global lupus erythematous market.
Report Description<br />
Additionally, safety <strong>and</strong> quality of systemic lupus erythematous controlling therapy may<br />
possibly be a challenge for the growth of the global systemic lupus erythematous drugs<br />
market. Moreover, numerous public awareness programs targeted to increase awareness<br />
levels are also being accompanied. For instance, <strong>Lupus</strong> Foundation of America (LFA) has<br />
been implementing various projects to increase central support for <strong>SLE</strong> research <strong>and</strong><br />
services to support people <strong>and</strong> families affected by <strong>SLE</strong>. However, serious side effectswith<br />
steroids, sensitivity with antibiotics, limited usage of Benlysta for severe <strong>SLE</strong> patients, <strong>and</strong><br />
stringent regulatory approvals for new treatment options with better levels of efficacy<br />
<strong>and</strong> safety are obstructing the global systemic lupus erythematous drugs market.<br />
Request for sample report: http://www.futuremarketinsights.com/reports/sample/repgb-1149<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> <strong>Market</strong>: Segmentation<br />
The global systemic lupus erythematous drugs market is classified on the basis of<br />
molecule <strong>and</strong> region.<br />
Based on type of molecule, the global systemic lupus erythematous drugs market is<br />
segmented into the following:<br />
Corticosteroids<br />
Prednisone<br />
Cortisone<br />
Hydrocortisone
Report Description<br />
•Non-Steroidal Anti-inflammatory <strong>Drugs</strong> (NSAIDs)<br />
• Over-the-counter NSAIDs include<br />
• Ibuprofen (Motrin)<br />
• Naproxen (Naprosyn)<br />
• Prescription versions include<br />
• Indomethacin (Indocin)<br />
• Nabumetone (RELAFEN)<br />
• Celecoxib (Celebrex)<br />
•Anti-Inflammatories<br />
• Aspirin<br />
• Acetaminophen (Tylenol)<br />
•Disease-Modifying Anti-Rheumatic <strong>Drugs</strong> (DMARDs)<br />
• Hydroxychloroquine (Plaquenil).<br />
• Cyclosporine (Gengraf, Neoral, S<strong>and</strong>immune)<br />
• Azathioprine (Azasan, Imuran)<br />
•Antimalarials<br />
• Chloroquine (Aralen)<br />
• Hydroxychloroquine (Plaquenil)
Report Description<br />
BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)<br />
Belimumab (Benlysta)<br />
Immunosuppressive Agents/Immune Modulators<br />
Azathioprine (Imuran)<br />
Methotrexate (Rheumatrex)<br />
Cyclophosphamide (Cytoxan)<br />
Anticoagulants<br />
Low-dose aspirin<br />
Heparin (Calciparine, Liquaemin)<br />
Warfarin (Coumadin)<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> <strong>Market</strong>: Overview<br />
Global systemic lupus erythematous drugs market growth is fast in North American region <strong>and</strong> is<br />
estimated to project remarkable CAGR growth throughout forecast period. In North America,<br />
the <strong>SLE</strong> is more prevalent among Hispanics, Asians, <strong>and</strong> Native Americans according to Centers<br />
for Disease Control <strong>and</strong> Prevention (CDC). The second largest <strong>and</strong> fastest growing global<br />
systemic lupus erythematous drugs market is Europe <strong>and</strong> is projected to reach nearly US$ 550<br />
Mn <strong>and</strong> register a double digit CAGR due to higher prevalence of <strong>SLE</strong> in Europe. Among the<br />
European countries Sweden, Icel<strong>and</strong>, Spain had the highest prevalence according to <strong>Lupus</strong><br />
Journal article, published in 2006. A drug called hydroxychloroquine being the last drug was<br />
approved by FDA in 1955 for <strong>SLE</strong> treatment.
Report Description<br />
Recently, a drug called belimumab has been approved by FDA after 50 years long gap specifically<br />
for <strong>SLE</strong> on March 9, 2011. It is the first ever targeted biological drug for the treatment of <strong>SLE</strong><br />
patients developed by Human Genome Sciences Inc. in collaboration with GlaxoSmithKline. It<br />
will be the primary driver for global systemic lupus erythematous drugs market growth in the<br />
US, France, Germany, Italy Spain, the UK <strong>and</strong> Japan. Benlysta will lead market sales in coming<br />
years beca<strong>use</strong> of its excellent safety profile as well as proven efficacy in clinical trials. NSAIDS<br />
such as Ibuprofen <strong>and</strong> aspirin are widely prescribed drugs for suppressing symptoms of <strong>SLE</strong>.<br />
Immunosuppressants by Roche (CellCept (Mycophenolate mofetil), by Novartis (Neoral<br />
(Cyclosporine)), by GSK (Imuran (Azathioprine)) are also commonly prescribed for <strong>SLE</strong><br />
treatment. Additionally, the entry of four first-in-class (FIC) biologics such as Bristol-Myers<br />
Squibb’s Orencia (abatacept), atacicept, epratuzumab <strong>and</strong> LY2127399 are anticipated to show a<br />
major role in the expansion of the global systemic lupus erythematous drugs market.<br />
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1149<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> <strong>Market</strong>: Key Players<br />
The global systemic lupus erythematous drugs market key players are Anthera<br />
Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics,<br />
Johnson <strong>and</strong> Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.
Thank You!<br />
To know more about us, please visit our website:<br />
www.futuremarketinsights.com<br />
For sales queries or new topics email us on:<br />
sales@futuremarketinsights.com<br />
Future <strong>Market</strong> Insights: 616 Corporate Way, Suite 2-9018,<br />
Valley Cottage, NY 10989, United States<br />
T: +1-347-918-3531 | D: +1-845-579-5705
Change language